Evidence map›Paper›PMID 38935343›Full record

ArticleActa crystallographica. Section D, Structural biology2024

Towards a dependable data set of structures for L-asparaginase research.

Alexander Wlodawer, Zbigniew Dauter, Jacek Lubkowski, Joanna I Loch, Dariusz Brzezinski, Miroslaw Gilski, Mariusz Jaskolski

Abstract read
In one paragraph

Article in Acta crystallographica. Section D, Structural biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Duplicate entries in the Protein Data Bank: how to detect and handle them.Acta crystallographica. Section D, Structural biology · 2025
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexander WlodawerCenter for Structural Biology, Center for Cancer Research, National Cancer Institute, Maryland, USA.ORCID 0000-0002-5510-9703
Zbigniew DauterCenter for Structural Biology, Center for Cancer Research, National Cancer Institute, Maryland, USA.ORCID 0000-0002-8806-9066
Jacek LubkowskiCenter for Structural Biology, Center for Cancer Research, National Cancer Institute, Maryland, USA.
Joanna I LochDepartment of Crystal Chemistry and Crystal Physics, Faculty of Chemistry, Jagiellonian University, Cracow, Poland.ORCID 0000-0002-7345-4527
Dariusz BrzezinskiInstitute of Computing Science, Poznan University of Technology, Poznan, Poland.ORCID 0000-0001-9723-525X
Miroslaw GilskiInstitute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.ORCID 0000-0002-3941-9947
Mariusz JaskolskiInstitute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland.ORCID 0000-0003-1587-6489

Funding

Narodowe Centrum Nauki 2020/37/B/NZ1/03250Narodowe Centrum Nauki 2020/38/E/NZ1/00035
6 · The paper itself

Abstract

The Protein Data Bank (PDB) includes a carefully curated treasury of experimentally derived structural data on biological macromolecules and their various complexes. Such information is fundamental for a multitude of projects that involve large-scale data mining and/or detailed evaluation of individual structures of importance to chemistry, biology and, most of all, to medicine, where it provides the foundation for structure-based drug discovery. However, despite extensive validation mechanisms, it is almost inevitable that among the ∼215 000 entries there will occasionally be suboptimal or incorrect structure models. It is thus vital to apply careful verification procedures to those segments of the PDB that are of direct medicinal interest. Here, such an analysis was carried out for crystallographic models of L-asparaginases, enzymes that include approved drugs for the treatment of certain types of leukemia. The focus was on the adherence of the atomic coordinates to the rules of stereochemistry and their agreement with the experimental electron-density maps. Whereas the current clinical application of L-asparaginases is limited to two bacterial proteins and their chemical modifications, the field of investigations of such enzymes has expanded tremendously in recent years with the discovery of three entirely different structural classes and with numerous reports, not always quite reliable, of the anticancer properties of L-asparaginases of different origins.

Indexed as

AsparaginaseDatabases, ProteinCrystallography, X-RayHumansModels, MolecularProtein ConformationAsparaginaseamidohydrolaseshydrolasesl-asparaginasesleukemiaProtein Data Bank

Identifiers

PMID38935343
PMCPMC11220836

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.